A small biotech client had developed an asset that was a potential treatment for Idiopathic Pulmonary Fibrosis (IPF). Simbec-Orion was able to provide regulatory advice and support for submission to the MHRA, EMA and FDA, along with a study program that accelerated the delivery of their studies, saved cost and facilitated the transition from Healthy Volunteers (HV) to Phase II trials.
Who We Are